Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$142.50
At close: Jun 25, 4:03 PM EDT
$142.50
0.000.00%
After Hours: 4:03 PM EDT
Comments
Loading...
Krystal Biotech Analyst Ratings and Price Targets | NASDAQ:KRYS | Benzinga
Krystal Biotech Inc has a consensus price target of $189.08 based on the ratings of 13 analysts. The high is $245 issued by Jefferies on March 5, 2025. The low is $140 issued by B of A Securities on May 25, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Citigroup, and Guggenheim on June 24, 2025, May 16, 2025, and May 7, 2025, respectively. With an average price target of $194.67 between HC Wainwright & Co., Citigroup, and Guggenheim, there's an implied 36.61% upside for Krystal Biotech Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Citigroup
Guggenheim
Chardan Capital
Jefferies
1calculated from analyst ratings
Analyst Ratings for Krystal Biotech
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/24/2025 | Buy Now | 68.42% | HC Wainwright & Co. | Joseph Pantginis45% | $240 → $240 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2025 | Buy Now | 8.77% | Citigroup | Yigal Nochomovitz54% | $215 → $155 | Maintains | Neutral | Get Alert |
| 05/07/2025 | Buy Now | 32.63% | Guggenheim | Debjit Chattopadhyay53% | $195 → $189 | Maintains | Buy | Get Alert |
| 05/07/2025 | Buy Now | 53.68% | Chardan Capital | Geulah Livshits49% | $219 → $219 | Maintains | Buy | Get Alert |
| 05/06/2025 | Buy Now | 68.42% | HC Wainwright & Co. | Joseph Pantginis45% | $240 → $240 | Reiterates | Buy → Buy | Get Alert |
| 04/29/2025 | Buy Now | 68.42% | HC Wainwright & Co. | Joseph Pantginis45% | $221 → $240 | Maintains | Buy | Get Alert |
| 04/28/2025 | Buy Now | 68.42% | HC Wainwright & Co. | Joseph Pantginis45% | $221 → $240 | Maintains | Buy | Get Alert |
| 03/05/2025 | Buy Now | 71.93% | Jefferies | Roger Song36% | → $245 | Initiates | → Buy | Get Alert |
| 02/28/2025 | Buy Now | 55.09% | HC Wainwright & Co. | Joseph Pantginis45% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 02/20/2025 | Buy Now | 50.88% | Citigroup | Yigal Nochomovitz54% | $206 → $215 | Maintains | Neutral | Get Alert |
| 02/20/2025 | Buy Now | 50.88% | Cantor Fitzgerald | Josh Schimmer56% | → $215 | Reiterates | Overweight → Overweight | Get Alert |
| 02/20/2025 | Buy Now | 52.98% | Chardan Capital | Geulah Livshits49% | $212 → $218 | Maintains | Buy | Get Alert |
| 02/19/2025 | Buy Now | 55.09% | HC Wainwright & Co. | Joseph Pantginis45% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2024 | Buy Now | 48.77% | Chardan Capital | Geulah Livshits49% | $212 → $212 | Maintains | Buy | Get Alert |
| 12/18/2024 | Buy Now | 55.09% | HC Wainwright & Co. | Joseph Pantginis45% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2024 | Buy Now | 55.09% | HC Wainwright & Co. | Joseph Pantginis45% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | 48.77% | Chardan Capital | Geulah Livshits49% | $212 → $212 | Maintains | Buy | Get Alert |
| 12/10/2024 | Buy Now | 55.09% | HC Wainwright & Co. | Joseph Pantginis45% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 11/05/2024 | Buy Now | 44.56% | Citigroup | Yigal Nochomovitz54% | $204 → $206 | Maintains | Neutral | Get Alert |
| 11/05/2024 | Buy Now | 55.09% | HC Wainwright & Co. | Joseph Pantginis45% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2024 | Buy Now | 54.39% | Stifel | Dae Gon Ha49% | $204 → $220 | Maintains | Buy | Get Alert |
| 08/29/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer56% | — | Reiterates | → Overweight | Get Alert |
| 08/29/2024 | Buy Now | 55.09% | HC Wainwright & Co. | Joseph Pantginis45% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2024 | Buy Now | 55.09% | HC Wainwright & Co. | Joseph Pantginis45% | $200 → $221 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | 44.56% | Evercore ISI Group | Gavin Clark-Gartner38% | $201 → $206 | Maintains | Outperform | Get Alert |
| 08/06/2024 | Buy Now | 43.16% | Citigroup | Yigal Nochomovitz54% | $195 → $204 | Downgrade | Buy → Neutral | Get Alert |
| 08/05/2024 | Buy Now | 45.96% | Chardan Capital | Geulah Livshits49% | $153 → $208 | Maintains | Buy | Get Alert |
| 08/05/2024 | Buy Now | 40.35% | HC Wainwright & Co. | Joseph Pantginis45% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 40.35% | HC Wainwright & Co. | Joseph Pantginis45% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 05/06/2024 | Buy Now | 40.35% | HC Wainwright & Co. | Joseph Pantginis45% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 04/22/2024 | Buy Now | 40.35% | HC Wainwright & Co. | Joseph Pantginis45% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 04/16/2024 | Buy Now | 43.16% | Stifel | Dae Gon Ha49% | $178 → $204 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2024 | Buy Now | 36.84% | Citigroup | Yigal Nochomovitz54% | $160 → $195 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | 22.81% | Guggenheim | Debjit Chattopadhyay53% | $130 → $175 | Maintains | Buy | Get Alert |
| 12/13/2023 | Buy Now | 26.32% | Cantor Fitzgerald | Josh Schimmer56% | $160 → $180 | Maintains | Overweight | Get Alert |
| 11/20/2023 | Buy Now | 12.28% | Goldman Sachs | Andrea Tan40% | → $160 | Initiates | → Buy | Get Alert |
| 11/07/2023 | Buy Now | 12.28% | Cantor Fitzgerald | Josh Schimmer56% | → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 10/24/2023 | Buy Now | 12.28% | Cantor Fitzgerald | Josh Schimmer56% | → $160 | Initiates | → Overweight | Get Alert |
| 10/12/2023 | Buy Now | 12.28% | Citigroup | Carly Kenselaar66% | → $160 | Initiates | → Buy | Get Alert |
| 09/07/2023 | Buy Now | 8.07% | Berenberg | Caroline Palomeque59% | → $154 | Initiates | → Buy | Get Alert |
| 08/08/2023 | Buy Now | 7.37% | Chardan Capital | Geulah Livshits49% | $148 → $153 | Maintains | Buy | Get Alert |
| 08/07/2023 | Buy Now | -2.46% | HC Wainwright & Co. | Joseph Pantginis45% | → $139 | Reiterates | Buy → Buy | Get Alert |
| 07/27/2023 | Buy Now | -2.46% | HC Wainwright & Co. | Joseph Pantginis45% | → $139 | Reiterates | Buy → Buy | Get Alert |
| 07/03/2023 | Buy Now | -2.46% | HC Wainwright & Co. | Joseph Pantginis45% | → $139 | Reiterates | → Buy | Get Alert |
| 05/25/2023 | Buy Now | -1.75% | B of A Securities | Alec Stranahan32% | $118 → $140 | Maintains | Buy | Get Alert |
| 05/24/2023 | Buy Now | 1.75% | Stifel | Dae Gon Ha49% | $102 → $145 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | -8.77% | Guggenheim | Debjit Chattopadhyay53% | $101 → $130 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | 8.77% | Goldman Sachs | Madhu Kumar72% | $135 → $155 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | 3.86% | Chardan Capital | Geulah Livshits49% | $133 → $148 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | -2.46% | HC Wainwright & Co. | Joseph Pantginis45% | $119 → $139 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | -17.19% | B of A Securities | Alec Stranahan32% | $105 → $118 | Maintains | Buy | Get Alert |
| 05/07/2023 | Buy Now | -5.26% | Goldman Sachs | Madhu Kumar72% | → $135 | Maintains | Buy | Get Alert |
| 04/18/2023 | Buy Now | -28.42% | Stifel | Dae Gon Ha49% | → $102 | Initiates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | -29.12% | Guggenheim | Debjit Chattopadhyay53% | → $101 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | -16.49% | HC Wainwright & Co. | Joseph Pantginis45% | → $119 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | -12.98% | Goldman Sachs | Madhu Kumar72% | $79 → $124 | Upgrade | Neutral → Buy | Get Alert |
| 02/28/2023 | Buy Now | -6.67% | Chardan Capital | Geulah Livshits49% | → $133 | Reiterates | → Buy | Get Alert |
| 11/08/2022 | Buy Now | -6.67% | Chardan Capital | Geulah Livshits49% | $130 → $133 | Maintains | Buy | Get Alert |
| 11/07/2022 | Buy Now | -44.56% | Goldman Sachs | Madhu Kumar72% | $74 → $79 | Maintains | Neutral | Get Alert |
| 11/07/2022 | Buy Now | -16.49% | HC Wainwright & Co. | Joseph Pantginis45% | $107 → $119 | Maintains | Buy | Get Alert |
| 08/25/2022 | Buy Now | -48.07% | Goldman Sachs | Madhu Kumar72% | → $74 | Downgrade | Buy → Neutral | Get Alert |
| 08/09/2022 | Buy Now | -8.77% | Chardan Capital | Geulah Livshits49% | $137 → $130 | Maintains | Buy | Get Alert |
| 08/08/2022 | Buy Now | -48.07% | Goldman Sachs | Madhu Kumar72% | $78 → $74 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Krystal Biotech (KRYS) stock?
The latest price target for Krystal Biotech (NASDAQ:KRYS) was reported by HC Wainwright & Co. on June 24, 2025. The analyst firm set a price target for $240.00 expecting KRYS to rise to within 12 months (a possible 68.42% upside). 28 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Krystal Biotech (KRYS)?
The latest analyst rating for Krystal Biotech (NASDAQ:KRYS) was provided by HC Wainwright & Co., and Krystal Biotech reiterated their buy rating.
When was the last upgrade for Krystal Biotech (KRYS)?
The last upgrade for Krystal Biotech Inc happened on February 28, 2023 when Goldman Sachs raised their price target to $124. Goldman Sachs previously had a neutral for Krystal Biotech Inc.
When was the last downgrade for Krystal Biotech (KRYS)?
The last downgrade for Krystal Biotech Inc happened on August 6, 2024 when Citigroup changed their price target from $195 to $204 for Krystal Biotech Inc.
When is the next analyst rating going to be posted or updated for Krystal Biotech (KRYS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Krystal Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Krystal Biotech was filed on June 24, 2025 so you should expect the next rating to be made available sometime around June 24, 2026.
Is the Analyst Rating Krystal Biotech (KRYS) correct?
While ratings are subjective and will change, the latest Krystal Biotech (KRYS) rating was a reiterated with a price target of $240.00 to $240.00. The current price Krystal Biotech (KRYS) is trading at is $142.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
